Natixis Advisors LLC Boosts Stake in Haleon PLC Sponsored ADR $HLN

Natixis Advisors LLC raised its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 429.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,003,941 shares of the company’s stock after buying an additional 8,115,633 shares during the period. Natixis Advisors LLC owned 0.22% of Haleon worth $101,140,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Eagle Investment Management LLC increased its stake in Haleon by 9.8% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,056,951 shares of the company’s stock valued at $27,421,000 after buying an additional 273,044 shares during the last quarter. Cidel Asset Management Inc. purchased a new stake in Haleon in the 3rd quarter valued at about $4,043,000. Optiver Holding B.V. purchased a new stake in Haleon in the 3rd quarter valued at about $45,593,000. JPMorgan Chase & Co. increased its stake in Haleon by 36.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after buying an additional 3,207,986 shares during the last quarter. Finally, Third View Private Wealth LLC purchased a new stake in Haleon in the 4th quarter valued at about $3,461,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 1.5%

Shares of HLN stock opened at $8.71 on Wednesday. The company has a 50 day moving average of $9.51 and a 200-day moving average of $9.95. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 12-month low of $8.69 and a 12-month high of $11.30. The firm has a market cap of $38.56 billion, a P/E ratio of 22.32, a PEG ratio of 2.01 and a beta of 0.13.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The company had revenue of $3.65 billion for the quarter. Sell-side analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, Argus upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.